Phase 3 Trial Shows Baxdrostat Lowers Blood Pressure by About 10 mmHg in Hard-to-Control Hypertension

The aldosterone‑synthesis inhibitor delivered clinically meaningful reductions with a manageable safety profile as the sponsor prepares regulatory filings.